Saudi Pharmaceutical Industries and Medical Appliances Corporation

SASE:2070 Stock Report

Market Cap: ر.س4.5b

Saudi Pharmaceutical Industries and Medical Appliances Past Earnings Performance

Past criteria checks 0/6

Saudi Pharmaceutical Industries and Medical Appliances has been growing earnings at an average annual rate of 13.6%, while the Pharmaceuticals industry saw earnings growing at 11.4% annually. Revenues have been declining at an average rate of 0.07% per year.

Key information

13.6%

Earnings growth rate

13.6%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate-0.07%
Return on equity-0.5%
Net Margin-1.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Not Lagging Industry On Growth Or Pricing

Mar 21
Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Not Lagging Industry On Growth Or Pricing

Is Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Worth ر.س38.1 Based On Its Intrinsic Value?

Jun 26
Is Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Worth ر.س38.1 Based On Its Intrinsic Value?

Is There An Opportunity With Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) 20% Undervaluation?

Mar 14
Is There An Opportunity With Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) 20% Undervaluation?

Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) Intrinsic Value Is Potentially 52% Above Its Share Price

Aug 02
Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) Intrinsic Value Is Potentially 52% Above Its Share Price

Saudi Pharmaceutical Industries and Medical Appliances' (TADAWUL:2070) Dividend Is Being Reduced To ر.س0.60

May 19
Saudi Pharmaceutical Industries and Medical Appliances' (TADAWUL:2070) Dividend Is Being Reduced To ر.س0.60

One Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Analyst Just Made A Major Cut To Next Year's Estimates

May 12
One Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Analyst Just Made A Major Cut To Next Year's Estimates

A Look At The Fair Value Of Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070)

Feb 20
A Look At The Fair Value Of Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070)

Saudi Pharmaceutical Industries and Medical Appliances' (TADAWUL:2070) Shareholders May Want To Dig Deeper Than Statutory Profit

Nov 18
Saudi Pharmaceutical Industries and Medical Appliances' (TADAWUL:2070) Shareholders May Want To Dig Deeper Than Statutory Profit

Does It Make Sense To Buy Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) For Its Yield?

Mar 30
Does It Make Sense To Buy Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) For Its Yield?

Should Saudi Pharmaceutical Industries and Medical Appliances (TADAWUL:2070) Be Disappointed With Their 50% Profit?

Feb 23
Should Saudi Pharmaceutical Industries and Medical Appliances (TADAWUL:2070) Be Disappointed With Their 50% Profit?

What You Need To Know About Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) Investor Composition

Jan 19
What You Need To Know About Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) Investor Composition

Is Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) At Risk Of Cutting Its Dividend?

Dec 16
Is Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) At Risk Of Cutting Its Dividend?

Revenue & Expenses Breakdown
Beta

How Saudi Pharmaceutical Industries and Medical Appliances makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SASE:2070 Revenue, expenses and earnings (SAR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,653-2061641
30 Sep 231,692-7165447
30 Jun 231,667-7565951
31 Mar 231,569-14467847
31 Dec 221,422-15263143
30 Sep 221,425-9458951
30 Jun 221,379-4256341
31 Mar 221,3943854736
31 Dec 211,4603053729
30 Sep 211,4715752714
30 Jun 211,53211751920
31 Mar 211,53411051320
31 Dec 201,55513053220
30 Sep 201,521-1146111
30 Jun 201,491-1536111
31 Mar 201,518-3656577
31 Dec 191,487-43465313
30 Sep 191,743-16358640
30 Jun 191,626-20459440
31 Mar 191,566655139
31 Dec 181,5037454140
30 Sep 181,3136651734
30 Jun 181,3666150037
31 Mar 181,3758545939
31 Dec 171,38613948837
30 Sep 171,31527458936
30 Jun 171,29529660531
31 Mar 171,32928965431
31 Dec 161,25927763331
30 Sep 161,44812456348
30 Jun 161,49914954441
31 Mar 161,59534755933
31 Dec 151,70535756125
30 Sep 151,6044575740
30 Jun 151,5624655700
31 Mar 151,5003255580
31 Dec 141,4703175520
30 Sep 141,4242835470
30 Jun 141,3812795280
31 Mar 141,3512955160
31 Dec 131,3112675020
30 Sep 131,2942644840
30 Jun 131,2992624740

Quality Earnings: 2070 is currently unprofitable.

Growing Profit Margin: 2070 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2070 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.6% per year.

Accelerating Growth: Unable to compare 2070's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2070 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.8%).


Return on Equity

High ROE: 2070 has a negative Return on Equity (-0.54%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.